Skip to main content

Research Repository

Advanced Search

All Outputs (2)

The adoption of open platform for container bookings in the maritime supply chain (2020)
Journal Article
Zeng, F., Chan, H. K., & Pawar, K. (2020). The adoption of open platform for container bookings in the maritime supply chain. Transportation Research Part E: Logistics and Transportation Review, 141, Article 102019. https://doi.org/10.1016/j.tre.2020.102019

Information systems and technologies (IST) have been playing increasingly crucial roles in supporting the smooth running of maritime supply chain operations. The degree of acceptance of IST within the maritime sector as a whole, however, remains frag... Read More about The adoption of open platform for container bookings in the maritime supply chain.

Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial (2017)
Journal Article
Bath, P. M., Christensen, L. M., Woodhouse, L. J., Bentsen, L., Appleton, J. P., Krarup Hansen, C., Beridze, M., Thomsen, T. T., Christensen, H., Kruuse, C., Dineen, R. A., Jensen, H. H., Duley, L., Hansen, S. S., England, T. J., Petrovic, V., Flaherty, K., Beridze, N., Havard, D., Kakabadze, N., …Farren, P. (2018). Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial. Lancet, 391(10123), 850-859. https://doi.org/10.1016/S0140-6736%2817%2932849-0

Background: Intensive antiplatelet therapy with three agents might be more effective than guideline treatment for preventing recurrent events in patients with acute cerebral ischaemia. We aimed to compare the safety and efficacy of intensive antiplat... Read More about Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial.